Barclays reiterated coverage on Arcus Biosciences with a new price target

11/19/21 7:43:41 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Barclays reiterated coverage of Arcus Biosciences with a rating of Overweight and set a new price target of $60.00 from $48.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$RCUS

Date	Price Target	Rating	Analyst
2/26/2025	$18.00 → $24.00	Neutral → Buy	H.C. Wainwright
10/21/2024	$20.00	Neutral	H.C. Wainwright
10/8/2024	$29.00	Overweight	Wells Fargo
11/18/2022	$33.00	Neutral	BofA Securities
10/11/2022	$40.00	Overweight	Morgan Stanley
11/19/2021	$42.00 → $53.00	Buy	Citigroup
11/19/2021	$48.00 → $60.00	Overweight	Barclays
11/18/2021	$68.00 → $100.00	Outperform	SVB Leerink